CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$13.0 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$13.0 million, down 130.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.8 million (down 219.86% YoY), and the FY2025 annual result was $4.3 million, down 55.76% from the prior year.
• Change in Accured Expenses came in at -$13.0 million for Q1 2026 at CRISPR Therapeutics AG, up from -$36.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $43.0 million in Q1 2025 to a low of -$36.2 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is -$9.2 million (2023), against an average of -$836235.3.
• Across the five-year window, Change in Accured Expenses soared 10019.0% in 2022 and tumbled 359.09% in 2023, its largest moves.
• CRISPR Therapeutics AG's Change in Accured Expenses stood at $7.3 million in 2022, then sank by 225.24% to -$9.2 million in 2023, then jumped by 416.15% to $29.1 million in 2024, then slumped by 224.63% to -$36.2 million in 2025, then jumped by 64.06% to -$13.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$13.0 million (Q1 2026), -$36.2 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.